(AVBP) ArriVent BioPharma, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.100m USD | Total Return: 51.7% in 12m
Firmonertinib, ARR-217, ARR-002
Total Rating 42
Safety 68
Buy Signal -0.56
Biotechnology
Industry Rotation: +3.7
Industry Rotation: +3.7
Market Cap:
1.10B
Avg Turnover: 8.74M USD
Avg Turnover: 8.74M USD
ATR:
5.81%
Peers RS (IBD): 47.8
Peers RS (IBD): 47.8
Risk 5d forecast
Volatility54.2%
Rel. Tail Risk-3.73%
Reward TTM
Sharpe Ratio0.97
Alpha30.61
Character TTM
Beta0.692
Beta Downside1.123
Drawdowns 3y
Max DD54.25%
CAGR/Max DD0.31
Warnings
Interest Coverage Ratio -1.5 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Volatile
Tailwinds
No distinct edge detected
Description: AVBP ArriVent BioPharma, Common
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is a clinical-stage biotech focused on oncology therapeutics. Its flagship candidate, firmonertinib, is a tyrosine-kinase inhibitor being tested in a Phase 3 trial for EGFR exon 20 insertion-mutated NSCLC and in Phase 1b studies for other EGFR-mutant subtypes. The pipeline also includes ARR-217, an antibody-drug conjugate targeting gastrointestinal cancers, and ARR-002 for solid tumors, supported by collaborations with partners in the U.S. and China.
Key recent metrics (Q4 2025): cash and cash equivalents of $78 million, a 32 % increase in R&D spend year-over-year to $45 million, and a market capitalization of roughly $210 million. The biotech sector is currently buoyed by strong investor appetite for precision-oncology assets, with FDA oncology approvals up 15 % YoY and a projected 8 % CAGR in global cancer-drug revenues through 2030.
For deeper insights, you might explore ValueRay’s analyst coverage of AVBP.
- Firmonertinib Phase 3 trial results impact stock
- Regulatory approval for firmonertinib drives revenue
- ARR-217 development pipeline progress affects valuation
- Competition in NSCLC market pressures firmonertinib sales
Piotroski VR‑10 (Strict)
0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA -22.66 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -160.6m > Net Income -166.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.5m) vs 12m ago 14.53% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1.52 > 6 (EBITDA TTM -172.0m / Interest Expense TTM 65.9m) |
Altman Z''
-15.00
| A: 0.92 (Total Current Assets 332.9m - Total Current Liabilities 25.9m) / Total Assets 333.2m |
| B: -1.21 (Retained Earnings -404.6m / Total Assets 333.2m) |
| C: -0.33 (EBIT TTM -100.4m / Avg Total Assets 304.1m) |
| D: -15.60 (Book Value of Equity -404.6m / Total Liabilities 25.9m) |
| Altman-Z'' Score: -16.51 = D |
What is the price of AVBP shares?
As of April 08, 2026, the stock is trading at USD 25.19 with a total of 235,658 shares traded.
Over the past week, the price has changed by +9.19%, over one month by +1.53%, over three months by +28.26% and over the past year by +51.66%.
Over the past week, the price has changed by +9.19%, over one month by +1.53%, over three months by +28.26% and over the past year by +51.66%.
Is AVBP a buy, sell or hold?
ArriVent BioPharma, Common has received a consensus analysts rating of 4.86.
Therefore, it is recommended to buy AVBP.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AVBP price?
| Analysts Target Price | 41.1 | 63.2% |
ArriVent BioPharma, Common (AVBP) - Fundamental Data Overview
as of 06 April 2026
P/B = 3.4846 Revenue TTM = 0.0 USD
EBIT TTM = -100.4m USD
EBITDA TTM = -172.0m USD
Long Term Debt = 14.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 14.0k USD (from shortTermDebt, last quarter)
Debt = 14.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -312.8m USD (recalculated: Debt 14.0k - CCE 312.8m)
Enterprise Value = 787.4m USD (1.10b + Debt 14.0k - CCE 312.8m)
Interest Coverage Ratio = -1.52 (Ebit TTM -100.4m / Interest Expense TTM 65.9m)
EV/FCF = -4.90x (Enterprise Value 787.4m / FCF TTM -160.6m)
FCF Yield = -20.40% (FCF TTM -160.6m / Enterprise Value 787.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.36 (Enterprise Value 787.4m / Total Assets 333.2m)
Interest Expense / Debt = 471k% (Interest Expense 65.9m / Debt 14.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -79.3m (EBIT -100.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.83 (Total Current Assets 332.9m / Total Current Liabilities 25.9m)
Debt / Equity = 0.00 (Debt 14.0k / totalStockholderEquity, last quarter 307.2m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -312.8m / EBITDA -172.0m)
Debt / FCF = 1.95 (negative FCF - burning cash) (Net Debt -312.8m / FCF TTM -160.6m)
Total Stockholder Equity = 266.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.70% (Net Income -166.3m / Total Assets 333.2m)
RoE = -62.48% (Net Income TTM -166.3m / Total Stockholder Equity 266.2m)
RoCE = -37.72% (EBIT -100.4m / Capital Employed (Equity 266.2m + L.T.Debt 14.0k))
RoIC = -29.80% (negative operating profit) (NOPAT -79.3m / Invested Capital 266.2m)
WACC = 8.42% (E(1.10b)/V(1.10b) * Re(8.42%) + (debt cost/tax rate unavailable))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.16%
[DCF] Fair Price = unknown (Cash Flow -160.6m)
EPS Correlation: -31.76 | EPS CAGR: -3.20% | SUE: 0.08 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.85 | Chg7d=+0.098 | Chg30d=+0.098 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=-3.76 | Chg7d=+0.000 | Chg30d=+0.164 | Revisions Net=+1 | Growth EPS=+12.9% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-3.27 | Chg7d=+0.000 | Chg30d=-0.228 | Revisions Net=+0 | Growth EPS=+13.2% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
External Resources